Suvratoxumab
- Generic Name
- Suvratoxumab
- Drug Type
- Biotech
- CAS Number
- 1629620-18-3
- Unique Ingredient Identifier
- 4L1997J4DF
- Background
Suvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893).
A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2
Phase 3
Terminated
- Conditions
- Ventilator Associated PneumoniaStaphylococcus Aureus
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Aridis Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05331885
- Locations
- π§πͺ
Research Site Bel03, Haine-Saint-Paul, Belgium
π§πͺResearch Site Bel02, Ottignies, Belgium
π§πͺResearch Site Bel05, Yvoir, Belgium
Study of the Efficacy and Safety of MEDI4893
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 213
- Registration Number
- NCT02296320
- Locations
- π¨π
Research Site, Lausanne, Switzerland
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 85
- Registration Number
- NCT01769417
- Locations
- πΊπΈ
Research Site, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath